SELLAS Life Sciences Group, Inc.
Report topline data for Phase 2a clinical trial of SLS009
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- Q4 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“commencement of the Phase 2a study of SLS009 in combination with azacitidine and venetoclax in relapsed and refractory AML, for which we expect topline data in the fourth quarter of 2023”
What we found
Evidence strength A What the grades mean
The company reported positive initial topline data for the Phase 2a clinical trial of SLS009 during the fourth quarter of 2023, meeting the stated deadline.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2024-03-28
“In the fourth quarter of 2023, we completed enrollment in the 45 mg (safety) dose cohort in the Phase 2a study and reported positive initial topline data.” ✓ confirmed on the page
Market reaction: the shares moved +15.4% against the S&P 500 over the three sessions around the disclosure (27 Mar 2024 to 2 Apr 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 2 versions
-
Version 1 · original · stated 10 Aug 2023
Deadline 31 Dec 2023 (“fourth quarter of 2023”) · wording expected
-
Version 2 · stated 8 Mar 2024
Deadline 31 Mar 2024 (“this quarter”)
“reporting topline data from our Phase 2a SLS009 r/r AML trial this quarter”
-
Version 3 · stated 14 May 2024
Deadline 30 Sep 2024 (“the Second and Third Quarter 2024”) · wording expected
“Additional Data Expected in the Second and Third Quarter 2024”
-
Version 4 · stated 13 Nov 2024
Deadline 31 Dec 2024 (“fourth quarter of 2024”) · wording expected
“Additional topline data updates are expected in the fourth quarter of 2024.”
-
Version 5 · stated 20 Mar 2025
Deadline 30 Jun 2025 (“in 1H 2025”) · wording expected
“Full Data and FDA Regulatory Path Feedback Expected in 1H 2025”
-
Version 6 · stated 12 May 2026
Deadline 31 Dec 2026 (“in Q4 2026”) · wording expected
“The topline data are expected in Q4 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline data for Phase 2a SLS009 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002018 · Corrections policy